

**IN THE CLAIMS:**

1. (Canceled)
2. (Currently amended) The spasmolytic method as claimed in claim [[1]] 12, characterized in that xenon is present in the spasmolytic in a therapeutically effective amount.
3. (Currently amended) The spasmolytic method as claimed in claim [[1]] 12, characterized in that the spasmolytic comprises further includes NO or an NO source in a therapeutically effective amount.
4. (Currently amended) A spasmolytic The method as claimed in claim [[1,]] 12, wherein the comprising xenon or a xenon-containing gas and a further spasmolytic which is are administered orally or intravenously as a combination product for simultaneous, separate or sequential use in the treatment of spasms.
5. (Currently amended) The spasmolytic method as claimed in claim 4, characterized in that the combination spasmolytic is used for the treatment of vasospasms.
6. (Currently amended) A medicament comprising xenon and an NO source or comprising, and wherein the xenon is selected from the group consisting of xenon and a xenon-containing gas and an NO source.
7. (Currently amended) The use of xenon or of a xenon-containing gas mixture according to claim 1, and, where appropriate, of an NO source to produce method as claimed in claim 12, where the spasmolytic is used as a medicament for the a treatment of conditions selected from the group consisting of spasms, to produce a medicament for

~~the treatment of vasospasms, to produce a medicament for the treatment of cerebral vasospasms, to produce a medicament for the treatment of impairments of blood flow, in particular to produce a gaseous medicament for the treatment of impairments of blood flow in the brain, to produce a medicament for the treatment of impairment of cerebral perfusion, to produce a medicament for the treatment of coronary perfusion impairment, to produce a medicament for the treatment of cognitive impairments, to produce a medicament for the treatment of stroke, to produce a medicament for the prophylaxis of stroke, to produce a medicament for improving the oxygen supply in the brain, to produce a medicament for the treatment of post-ischemia syndrome or to produce a medicament for promoting blood flow in the brain, to produce a medicament for improving the oxygenation of the body, and to produce a medicament for improving the oxygenation of the brain.~~

8. (Currently amended) The ~~use of xenon or of a xenon-containing gas mixture method~~ according to claim [[1,]] 12, wherein the xenon is used to produce a medicament having a vasodilating effect in capillary or precapillary vascular systems of the human body.

9. (Currently amended) The ~~use of xenon or of a xenon-containing gas mixture method~~ according to claim 4, and, where appropriate, of 12, wherein the spasmolytic includes an NO source to produce a medicament for the prophylaxis and/or therapy of impairments of cognitive performance, also postoperatively.

10. (Currently amended) The ~~use of xenon or of a xenon-containing gas mixture method according to claim 4, and, where appropriate, of 12, wherein the spasmolytic includes~~ an NO source for the treatment of spasms.
11. (Currently amended) The ~~use of xenon or of a xenon-containing gas, oxygen and, where appropriate, of method according to claim 12, wherein the spasmolytic includes~~ an NO source for supplying oxygen to spontaneously breathing patients.
12. (New) A method of using xenon in the form of xenon or a xenon-containing gas mixture characterized in that the xenon is used as a spasmolytic.
13. (New) The method according to claim 7, wherein the medicament is a gaseous medicament used for the treatment of impairments of blood flow.
14. (New) The method according to claim 7, wherein an NO source is included in the medicament.
15. (New) The method according to claim 12, wherein the spasmolytic is used as a medicament for the prophylaxis and/or therapy of impairments of cognitive performance, also postoperatively.
16. (New) The method according to claim 12, wherein the spasmolytic is used for the treatment of spasms.
17. (New) The method according to claim 12, wherein the spasmolytic is used in supplying oxygen to spontaneously breathing patients.